

THERAVANCE INC  
Form 8-K  
July 02, 2012

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

---

FORM 8-K

---

Current Report Pursuant  
to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): July 2, 2012

---

THERAVANCE, INC.  
(Exact Name of Registrant as Specified in its Charter)

---

|   |                                       |  |
|---|---------------------------------------|--|
| Delaware<br>(State or Other Jurisdiction of<br>Incorporation) | 000-30319<br>(Commission File Number) | 94-3265960<br>(I.R.S. Employer Identification<br>Number) |
|---|---------------------------------------|--|

901 Gateway Boulevard  
South San Francisco, California 94080  
(650) 808-6000

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On July 2, 2012, GlaxoSmithKline (GSK) and Theravance, Inc. (the “Company”) issued a press release announcing the results of four pivotal Phase 3a studies of the once-daily investigational LAMA/LABA (GSK573719 or umeclidinium bromide (UMEC)/vilanterol (VI)) in patients with chronic obstructive pulmonary disease (COPD). UMEC/VI is a combination of two investigational bronchodilator molecules – UMEC, a long-acting muscarinic antagonist and VI, a long-acting beta2 agonist, currently in development under the LABA collaboration agreement between GSK and the Company, for the treatment of COPD. Members of the Company’s management will discuss the announcement on a conference call today at 8:00 a.m. Eastern Daylight Time.

A copy of the press release is filed as Exhibit 99.1 to this report and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

| Exhibit      | Description                      |
|--------------|----------------------------------|
| Exhibit 99.1 | Press Release Dated July 2, 2012 |

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THERAVANCE, INC.

Date: July 2, 2012

By: /s/ Michael W. Aguiar  
Michael W. Aguiar  
Chief Financial Officer

EXHIBIT INDEX

| Exhibit | Description |
|---------|-------------|
|---------|-------------|

|              |                                  |
|--------------|----------------------------------|
| Exhibit 99.1 | Press Release Dated July 2, 2012 |
|--------------|----------------------------------|

---

